Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.
Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in a suit filed Friday.
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.76%. June E-mini S&P futures (ESM26 ) rose +0.61%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.81%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.74%. June E-mini S&P futures (ESM26 ) are up +0.77%, and June E-mini Nasdaq futures...
CVS Health Corporation (NYSE:CVS) is one of the best medical stocks to invest in according to billionaires. Morgan Stanley lifted the price target on CVS Health Corporation (NYSE:CVS) to $106 from $93 on May 14, maintaining an Overweight rating on the shares. CVS Health Corporation (NYSE:CVS) also received a rating update from Bernstein on May 13, […]
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
With an annual dividend yield of 2.84%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 20, Mizuho bumped up its price […]
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
CVS sued Tennessee after Gov. Bill Lee signed legislation to prohibit companies from owning both pharmacy benefit managers and retail pharmacies.
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
CVS Health Corporation (NYSE:CVS) is included among the 10 High Quality Stocks to Buy According to Hedge Funds. On May 13, Bernstein raised its price recommendation on CVS Health Corporation (NYSE:CVS) to $106 from $94. It reiterated an Outperform rating on the stock. The firm said it still sees CVS as well-positioned to benefit from […]
Hospitals affiliated with Mount Sinai, the University of Michigan and the University of Kansas allege that CVS artificially deflated reimbursement for 340B drugs for years, causing them to lose out on savings.
Three major hospital systems have accused CVS of allegedly diverting hundreds of millions from the federal 340B Drug Pricing Program.
Don’t be surprised if you see more jewelry or hair accessories during your next trip to CVS, Walmart, or Kohl’s.
CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount program. The University of Kansas Hospital Authority and the University of Michigan Hospitals and Health Centers allege CVS Health improperly profited from 340B discounts. Combined claimed damages exceed $60 million, raising legal, financial, and reputational questions for the company. CVS Health comes into this legal pressure with its shares at $93.28 and a return of...
Claire's filed for Chapter 11 bankruptcy in August 2025, the chain's second bankruptcy filling in seven years.
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
CVS is more than a dividend play.
Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.
The president’s financial disclosures reveal several trades in UnitedHealth and other insurers as the government set Medicare rate policies.
Looking past stocks because they trade at high trailing earnings multiples can be a costly mistake for investors.
Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution. They negotiate rebates, design formularies, adjudicate claims, and steer patient adherence. Modern artificial intelligence (AI) is designed to compress each of these high-volume, rules-driven processes. As autonomous prior authorization, real-time formulary optimization, and AI-driven rebate analytics scale, the Big Three PBMs face a ... AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
A licensing agreement with Centric Brands will scale the retailer’s presence across partners, including Walmart, Kohl’s and CVS and will push the brand into new categories.